The fast-growing fish can now be raised and sold in the US, although it’s likely to be some time before the product hits the market.

Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.

President Trump’s pick, Judge Brett Kavanaugh, has often opposed court involvement in environmental and health regulations.

Medical groups have criticized the legislation, which will give terminal patients access to experimental treatments, as dangerous and unnecessary.

Two patients became legally blind after receiving treatments at the facilities.

The Scientist speaks with a clinical toxicologist to discuss how the supplement acts in the brain and what the agency's declaration means for research.

Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.